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CYP17A1 deficient XY mice display 
susceptibility to atherosclerosis, 
altered lipidomic profile and 
atypical sex development
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CYP17A1 is a cytochrome P450 enzyme with 17-alpha-hydroxylase and C17,20-lyase activities. 
CYP17A1 genetic variants are associated with coronary artery disease, myocardial infarction and 
visceral and subcutaneous fat distribution; however, the underlying pathological mechanisms remain 
unknown. We aimed to investigate the function of CYP17A1 and its impact on atherosclerosis in 
mice. At 4–6 months, CYP17A1-deficient mice were viable, with a KO:Het:WT ratio approximating 
the expected Mendelian ratio of 1:2:1. All Cyp17a1 knockout (KO) mice were phenotypically female; 
however, 58% were Y chromosome-positive, resembling the phenotype of human CYP17A1 deficiency, 
leading to 46,XY differences/disorders of sex development (DSD). Both male and female homozygous 
KO mice were infertile, due to abnormal genital organs. Plasma steroid analyses revealed a complete 
lack of testosterone in XY-KO mice and marked accumulation of progesterone in XX-KO mice. Elevated 
corticosterone levels were observed in both XY and XX KO mice. In addition, Cyp17a1 heterozygous 
mice were also backcrossed onto an Apoe KO atherogenic background and fed a western-type diet 
(WTD) to study the effects of CYP17A1 on atherosclerosis. Cyp17a1 x Apoe double KO XY mice 
developed more atherosclerotic lesions than Apoe KO male controls, regardless of diet (standard or 
WTD). Increased atherosclerosis in CYP17A1 XY KO mice lacking testosterone was associated with 
altered lipid profiles. In mice, CYP17A1 deficiency interferes with sex differentiation. Our data also 
demonstrate its key role in lipidomic profile, and as a risk factor in the pathogenesis of atherosclerosis.
Coronary artery disease (CAD) is a major cause of morbidity and mortality worldwide1. Inheritance plays an 
essential role in the pathogenesis of CAD, and recent genome-wide association studies (GWAS) have revealed 
more than 160 genomic loci associated with this condition2. One commonly reported genomic locus, for CAD 
was located at chr10p24.32. The same locus is also associated with myocardial infarction (MI)3 and visceral and 
subcutaneous fat distribution4. This locus harbors the CYP17A1 gene, which encodes the cytochrome P450 17A1 
enzyme, also referred to as steroid 17-alpha-monooxygenase or 17α-hydroxylase/17,20-lyase/17,20-desmolase. 
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Mutations affecting CYP17A1 function are reported to cause congenital adrenal hyperplasia (CAH), a rare inher-
ited disorder that affects both sexes. Approximately 1 in 13,000 to 15,000 children are born with CAH5, with 
mutations in CYP17A1 accounting for 1% of CAH in most populations6. In Brazil, mutations in CYP17A1 are 
frequent among patients with CAH, representing the second most common cause of the condition7. CYP17A1 
is a critical factor in the steroidogenic pathway producing progestins, glucocorticoids, androgens, estrogens, and 
mineralocorticoids. In addition to adrenal steroid biosynthesis CYP17A1-deficiency also affects gonadal steroid 
biosynthesis manifesting as disorders/differences of sex development (DSDs), leading to female or ambiguous 
external genitalia in 46,XY individuals and lack of pubertal development in boys and girls8,9.
CYP17A1 is a key microsomal enzyme that converts pregnenolone and progesterone to their major down-
stream products: dehydroepiandrosterone (DHEA), cortisol, testosterone, and estradiol10,11. Published evidence 
indicates an association between steroid hormone imbalance and traditional risk factors for CAD. Furthermore, 
estrogens can have a critical role in CAD, depending on sex; they appear to be detrimental in men and protec-
tive in women. More specifically, increased risk of CAD and MI is associated with early menopause in women, 
while high levels of endogenous estrogens are thought to explain the low prevalence of CAD in pre-menopausal 
women12–15. However, in men high levels of estrogens and estrone are associated with increased risk for MI and 
CAD16,17, while lower testosterone levels have been linked to increased risk for CAD18–20. Castration of Apoe 
knockout male mice led to increase atherosclerosis20.
While there is strong evidence that CYP17A1 enzyme synthesis is critical in the steroidogenic pathway to pro-
duce progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens, the functional role of CYP17A1 
in CAD remains unclear, and animal disease models are required to facilitate in-depth understanding of the 
underlying molecular mechanisms. In this context, we generated CYP17A1-deficient mice and studied the impact 
of lack of this gene on steroid metabolism, as well as its roles in atherosclerosis and lipid metabolism.
Materials and methods
Ethics statement. All animal experiments were approved by the German animal studies committee of 
Schleswig-Holstein, and animals were maintained and handled according to international guidelines.
Generation of Cyp17a1 knockout (KO) mice. The Cyp17a1 knockout embryonic stem cell 
(Cyp17a1-KO-ESC) line (EPD0214_2_B11) was purchased from the European Conditional Mouse Mutagenesis 
Program (EUCOMM). After quality control testing, microinjection of Cyp17a1-KO-ESC into C57BL/6N blasto-
cysts was achieved. The Cyp17a1 targeting vector (Fig. 1a) includes a neomycin selection cassette and two LoxP 
sites flanking exons 4 and 6 in the Cyp17a1 genomic sequence. It is also designed as Knockout-first. More spe-
cificaly, Cyp17a gene expression was interrupted by splicing exon 3 to the ß-galactosidase sequence 3′ of exon 3 
(Fig. 1a). The introduced sequence includes En2 splice acceptor (En2 SA) and the SV40 polyadenylation sequences 
Figure 1. Generation and characteristics of Cyp17a1 KO mice. (a) Targeting vector used to generate Cyp17a1 
KO mice. (b) Genotyping of mice by PCR (1: XX, Cyp17a1(+/+)xApoe(d/d); 2: XX,Cyp17a1(d/d)xApoe(d/d); 
3: XY,Cyp17a1(d/d)xApoe (d/d); 4: XY,Cyp17a1(+/+)xApoe(d/d); 5: XX, Cyp17a1(+/+)xApoe(+/+) control; 
6: XX, Cyp17a1(d/d)xApoe(d/d) control; 7: H2O; M: 100 bp marker). (c) The female appearance of XY KO mice. 
(d) Increased body weight of an XX KO mouse, compared with a control XX WT littermate. (e) Increased 
visceral fat in an XX KO mouse compared with a control littermate.
3Scientific RepoRtS |         (2020) 10:8792  | https://doi.org/10.1038/s41598-020-65601-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
(Fig. 1a). Male chimeras were obtained and backcrossed to C57BL/6J females in our animal house to generate 
heterozygous founders with a C57BL/6J genetic background. As both male and female homozygous knockout 
mice were infertile, backcrosses were conducted using heterozygous animals. Mice were backcrossed for at least 
six further generations to generate Cyp17a1 KO mice on a C57BL/6J background. The following primer pairs 
were used for the characterization of the knockout mice: Cyp17A1_LoxP F_TCCAGGTAAGCCTTTCTTCC/R_
AGAACCCTCCCCCATTCTC flanking the LoxP site in the intronic region between exon 6 and 7; ZFY_F 
AAGATAAGCTTACATAATCACATGGA/R_CCTATGAAATCCTTTGCTGCACATGT for the detection of 
the Y chromosome.
Breeding of the Cyp17a1 KO onto an atherogenic Apoe KO background. C57BL/6J mice [wild 
type (WT)] and Apoe(d/d) atherogenic mice were purchased from Charles River (Germany). To study the role 
of CYP17A1 in atherosclerosis, Cyp17a1(+/d) mice were mated with Apoe(d/d) animals to generate and select 
Cyp17a1(+/d) x Apoe(d/d) littermates, which were further bred together to produce Cyp17a1(d/d) x Apoe(d/d) 
and Apoe(d/d) mice as controls. WT mice (not on the Apoe(d/d) background) were used as non-atherogenic 
controls. Genotyping was conducted as previously described21. PCR was used to confirm the disruption of Apoe, 
according to a standard protocol from the Jackson Laboratory.
Analysis of Cyp17a1 expression. Immunohistochemisty. Embryos, gonadal and aorta tissue had 
been fixed in 4% paraformaldehyde and embedded in paraffin. Slices were pretreated with sodium citrate 
buffer (10 mM sodium citrate, 0.05% Tween 20) for epitope demasking and 0.3% hydrogen peroxide to reduce 
non-specific background due to endogenous peroxidase. CYP17A1 was detected using goat polyclonal antibody 
sc-46081 (Santa Cruz Biotechnology, Inc) at a dilution of 1:50 and an anti-goat biotinylated secondary antibody 
(Vectastain BA-5000, Vector Laboratories Inc., Burlingame, CA, USA). Bound antibodies were visualized using 
the ABC kit (Vectastain, PK-4000) and DAB 2 component chromogen kit (DCS. Hamburg, Germany) or using 
using donkey anti-goat AP antibody (Supplementary Fig. 2a,b).
X-gal staining of cryosections. Organs were excised and embedded in Tissue Tek (Sakura), snap frozen in liquid 
nitrogen, and stored at −20 °C until use. The X-gal staining was performed as previously reported by our group22. 
Briefly, cryosections of 8–10 μm were air dried and incubated in PBS containing 0.5% glutaraldehyde at 4 °C for 
10 min and incubated with X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) solution at 37 °C over-
night. Sections were counter-stained with Nuclear Fast Red, dehydrated and mounted using cover slips (Fisher).
qPCR analysis. The analysis was performed as described previously21,23. Briefly, total RNA was isolated from 
different cultured cells or purchased from commercially available human tissues (Origene) such as Heart 
(HT1002), Kidney (HT1003), and Liver (HT1005) using the RNeasy kit (Qiagen, Valencia, CA, USA) and reverse 
transcribed into cDNA. mRNA level of CYP17A1 was determined by relative quantitative RT-PCR and ana-
lysed using normalisation to GAPDH. The primers used for gene expression studies are as follow: For human 
samples analysis huCYP17A1-F/R: (TGGGCACCAAGACTACAGTG/GTTGTTGGACGCGATGTCTA) 
and huGAPDH-F/R: (GGATTTGGTCGTATTGGG/GGAAGATGGTGATGGGATT) were used. For mice 
mCyp17a1-F/R (GAGGGTATTGTGGATGTCCTG/GCATTTTTCAAACATTTCAACC) and mGAPDH-F/R 
(GACCACAGTCCATGCCATCAC/CCGTTCAGCTCTGGGATGAC) were used.
Analysis of atherosclerosis. Induction of atherosclerosis and collection of samples. Atherosclerotic plaque 
formation was analyzed in both male and female mice with four genotypes, Cyp17a1(d/d) x Apoe(d/d), Apoe(d/d), 
Cyp17a1(d/d), and controls (WT), at 10 weeks old. Each genotype was randomly divided into two groups 
(n = 6–8), which were fed either standard chow diet (chow) or a western-type diet (WTD), containing 0.2% 
cholesterol and 21.2% fat (TD.88137, Ssniff Spezialdiäten GmbH, Germany), for an additional 8 weeks. All mice 
were maintained under controlled conditions: temperature (23 °C), humidity (40–60%), and lighting (12 h/12 h 
light/dark cycle). Blood was collected from the retro-orbital sinus (following overnight fasting) in EDTA tubes 
and centrifuged at 4500 x g for 3 min at 4 °C to collect plasma. Plasma samples were collected in the same way 
before and after differential feeding with the WTD or standard chow. After 8 weeks on the allocated diet, mice 
were euthanized by inhalation of an overdose of isoflurane, sacrificed by cervical dislocation, and perfused with 
phosphate-buffered saline (pH 7.4) (Lonza, Cologne, Germany). Aortas (to the iliac bifurcation) and hearts were 
removed and fixed in 4% paraformaldehyde solution for histological analysis. Additional organs were collected 
for future studies. Tail biopsies were taken for re-genotyping. All samples for future RNA and protein studies were 
stored at −80 °C until further analysis.
Atherosclerosis analysis. To analyze atherosclerotic lesions in mice, atherosclerotic deposits were quantified in 
two types of aorta sample: 1) the whole aorta (from the aortic arch to the iliac bifurcation) and 2) the aortic root. 
All atherosclerotic plaque analyses were performed blind to the mouse genotype.
For the whole aorta, so-called ‘en-face’ analysis was conducted. Briefly, aortas were cleaned of fat and connec-
tive tissue, followed by removal of the adventitia. Then, aortas were opened longitudinally to expose the intimal 
surface and lipid-rich intraluminal lesions. Aortas were stained using Oil Red O (ORO) to detect atheroscle-
rotic deposits. Lesions were quantified from the aortic arch to the iliac bifurcation, including the brachiocephalic 
trunk, the left common carotid artery, and the left subclavian artery. Images were acquired using Leica equipment 
and Leica Application Suite (LAS) version 4.2 software (Leica Microsystems, Wetzlar, Germany). After omitting 
few mice due to bad quality of sectioning 6–8 animals were analyzed by a blinded observer using GIMP software, 
version 2.6 (The GIMP Development Team), and the ratio of ORO-positive lesions in each animal was deter-
mined as the percentage lesion area, normalized to the total area of the aorta.
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For quantification of atherosclerosis in the aortic root, including the aortic valves, 10 serial cross-sections (10 
μm thickness) were obtained, starting below the aortic root until the proximal aorta, below the aortic arch, using 
an in-house standardized protocol. The mean atherosclerotic lesion area was calculated using ORO staining from 
the 10 sections at 40 μm intervals, starting at the appearance of at least two aortic valves, as described previously24.
Blood lipid analysis. Blood lipids were detected in plasma samples, collected for all four genotypes. 
Hemolytic samples were discarded. Blood lipid analyses included determination of total cholesterol, high-density 
lipoprotein cholesterol (HDLC), direct low-density lipoprotein cholesterol (LDLC), and triglycerides. Samples 
were analyzed using a Roche Cobas 702 instrument at the Institute for Clinical Chemistry of the University of 
Lübeck.
Lipid profiling. Sample preparation. Plasma samples were extracted according to a modified version of the 
protocol of Pellegrino et al. using a mixture of methanol, methyl tertiary-butyl ether, and CHCl3 (1.33:1:1; v/v/v), 
to which butylated hydroxytoluene (100 mg/L, Sigma-Aldrich, Schnelldorf, Germany) and 2.5 µl of SPLASH 
internal standard mix (Avanti Polar Lipids, Alabaster, AL, USA) were added25. Samples were vortexed for 30 s, 
incubated at 25 °C on a shaker for 30 min, and centrifuged for 10 min at 2000 × g, and supernatants were col-
lected and dried under vacuum. Subsequently, samples were resuspended in 50 µl of methanol/isopropyl alcohol 
(1:1, v/v), centrifuged for 10 min at 16,000 × g, and transferred into liquid chromatography mass spectrometry 
(LC-MS) vials.
LC-MS analysis. Analysis was performed on an Orbitrap instrument (QExactive, ThermoFisher Scientific, 
Bremen, Germany) coupled to a Dionex Ultimate 3000 LC system (ThermoFisher Scientific, Bremen, Germany). 
Separation was performed on an Accucore C30 RP column (150 × 2.1 mm, particle size: 2.6 µm) using AcN/
H2O 6:4 (v/v), 0,1% FA as solvent A, and IPA/AcN (9:1, v/v), 0,1% FA as solvent B, flow was held at 0.26 ml/min. 
All solvents were of LC-MS grade quality and were purchased from Merck (Darmstadt, Germany). The follow-
ing gradient was used: Starting at 30% B ramping to 43% B after 2 min, to 55% B at 2.1 min to 65% B at 12 min, 
85% B at 18 min and 100% B after 20 min. Subsequently the columned was washed at 100% B for 15 min and 
re-equilibrated to starting conditions for 3 min26.
Data analysis. Data were recorded in positive and negative ion modes at resolutions of R = 70,000 for full scans 
and R = 17,500 for MS/MS scans. MS/MS data were generated using data-dependent acquisition. Data evaluation 
was performed using TraceFinder (ThermoFisher Scientific, Bremen, Germany). Lipid species were identified 
with an in-house library, according to exact mass, retention time, fragmentation ions, and isotopic pattern, using 
the same method as Karsai et al.27.
Steroid measurement. Various steroids, including progesterone, testosterone, deoxycorticosterone, 
corticosterone, and aldosterone, as well as estrogens including estrone (E1), estradiol (E2) and estriol (E3) 
(Concentrations less than 10 pmol/L were considered as not detectable) were measured in mouse plasma samples, 
according to protocols established for human analysis. All hormones were determined by LC-MS/MS, as previ-
ously described28,29. Briefly, sample aliquots, calibrators, and controls were combined with the internal standard 
mixture to monitor recovery. All samples were extracted using Oasis MAX SPE system plates (Waters, Milford, 
MA, USA). Chromatographic separation was carried out using an UPLC system, connected to a Quattro Premier/
XE triple Quad mass spectrometer (Waters, Milford, MA, USA). A Waters Acquity UPLC BEH C18 column 
(1.7 μm, 100 × 2.1) was used at a flow rate of 0.4 ml/min at 50 °C. Water (A) and acetonitrile (B) with 0.01% 
formic acid were used as the mobile phase. Two mass transitions were monitored for each hormone. The follow-
ing optimized parameters were used: capillary voltage, 3.5 kV; cone voltage, 28–33 V; collision energy, 18–25 eV; 
dwell time, 0.01–0.08 s, depending on the steroid; source temperature, 120 °C; and desolvation temperature, 
450 °C. Argon was used as the collision gas. Data were acquired using MassLynx 4.1 software and quantified with 
QuanLynx software (Waters, Milford, MA, USA). During all analyses, the ambient temperature was maintained 
at 21 °C by air conditioning.
Statistical analysis. Data are presented as the mean ± standard error of the mean (SEM). For multiple 
comparisons, one- or two-way ANOVA was used, as appropriate, followed by recommended post-hoc tests. For 
comparisons of two groups, unpaired t-tests were performed. Analyses were performed using GraphPad Version 
6.0d (GraphPad Software Inc., San Diego, CA). P-values <0.05 was considered statistically significant.
Results
Cyp17a1 KO mice had increased body weight and visceral/subcutaneous fat deposition, altered 
steroid metabolism, and altered lipid metabolism. After the generation of Cyp17a1 KO mice and 
confirmation of KO by PCR analysis at genomic DNA level (Fig. 1a,b), qPCR analysis at RNA level (Supplemental 
Fig. 2d) and immunhistostaining at protein level (Supplemental Figs. 1c,d and 2a,b), mice were initially charac-
terized in our laboratory at 4–6 months old. XY KO mice had a female appearance (external genital phenotype) 
(Fig. 1c); however, genotyping revealed a Mendelian ratio of XX and XY chromosomes (1:1), resembling the 
human phenotype in the rare form of the DSD and CAH, caused by CYP17A1 deficiency30. Evaluation of vari-
ous steroid hormones in plasma from KO mice revealed lack of testosterone synthesis and significantly elevated 
corticosterone and desoxycorticosterone levels in XY mice (Table 1). In XX mice, a marked accumulation of 
progesterone and a minor elevation of corticosterone levels were observed (Table 1).
In general, WT male mice have higher body weights than females. Cyp17a1 KO XX mice exhibited a marked 
increase in body weight, reaching values typical for WT males and significantly higher than those of WT females 
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(Fig. 1d, Table 2). In-depth characterization revealed higher visceral/subcutaneous fat deposition in XX KO mice 
(Fig. 1e).
Significant changes in LDLC levels were observed in both XY (increase) and XX (decrease) KO animals com-
pared to WT (Table 2). We also observed a significant increase of total cholesterol in XY KO mice. No significant 
differences were noted in, HDLC or triglycerides in females of different genotypes. In XY animals, there was a 
significant difference in total cholesterol between KO and WT animals (Table 2).
Cyp17a1 expression. Cyp17a1 KO mice were generated by insertion of a targeting vector containing a lacZ 
gene between exon 3 and 4 of Cyp17a1 (Fig. 1a). Insertion of lacZ into the Cyp17a1 gene allows monitoring of 
tissue-specific Cyp17a1 expression by X-gal staining. As expected, fertile heterozygous male mice show a strong 
tissue-specific expression of lacZ in the Leydig cells (Supplemental Fig. 1c). In addition a staining of the epithe-
lium of the epididymis was observed (Supplemental Fig. 1d). This tissue-specific expression was confirmed by 
CYP17A1 staining of testis from heterozygous embryos and WT males using polyclonal antibody sc-46081 (Santa 
Cruz Biotechnology) (Supplemental Fig. 1a,b,e).
Furthermore, we also used immunohistological staining to determine the expression of CYP17A1 in aor-
tic plaques of an old Apoe KO mouse with atherosclerotic deposits. Few infiltrated cells were found to express 
CYP17A1 at very low level (Supplemental Fig. 2c).
To test the expression of CYP17A1 in human materials we conducted gene expression analysis in differ-
ent cell lines that play a role during the initiation and development of atherosclerosis such as monocytes, aor-
tic smooth muscle cells (HASMCs) and endothelial cells (HUVECS). At basal conditions, none of those cells 
express CYP17A1 at RNA level. For HUVECS data are not shown. Similar to the mouse finding we noticed 
that monocyte-derived macrophages and synthetic confluent HASMCs express CYP17A1 at very low level 
(Supplemental Fig. 3). Further, Genotype-Tissue Expression (GTEx) datastet (v8) confirmed our expression 
results31.
Analysis of atherosclerosis. To study atherosclerosis in CYP17A1-deficient mice, animals were back-
crossed onto the atherogenic Apoe(d/d) background. At 10 weeks old, mice were divided into four groups (female 
and male of each of Cyp17a1(d/d) x Apoe(d/d) and Cyp17a1(+/+) x Apoe(d/d) and fed either a WTD or a stand-
ard chow diet for a further 8 weeks. Various parameters associated with atherosclerosis, including body weight, 
visceral fat deposits, and lipid parameters (total cholesterol, LDLC, HDLC, and triglycerides), were assessed in the 
mice, and atherosclerotic deposits in the entire aorta and the aortic root were evaluated.
CYP17A1-deficient mice on the Apoe(d/d) background exhibited increased body weight and visceral/subcutane-
ous fat deposition in XX females lacking Estrone. Similar to the observations in mice on a non-atherogenic 
background, increased body weight was observed only in Cyp17a1(d/d) x Apoe(d/d) XX mice consuming either 
standard chow or WTD, relative to the Apoe(d/d) controls (Fig. 2). No significant differences in body weight 
were observed between XY KO and XY WT. Only a slight increase in body weight was observed in each group 
attributable to the WTD. Furthermore, a dramatic increase in visceral fat deposition was observed in XX KO 
from the initiation of differential feeding to the end of the experiment in animals consuming both standard chow 
Hormones (in nmol/l)
XX mice
P-value
XY mice
P-value
Cyp17A 
(+/+) (n = 9) 
(mean ± SEM)
Cyp17A 
(d/d) (n = 6) 
(mean ± SEM)
Cyp17A 
(+/+) (n = 6) 
(mean ± SEM)
Cyp17A (d/d) 
(n = 12) 
(mean ± SEM)
Progesterone 8.53 ± 5.59 37.61 ± 0.9.88 0.001 1.08 ± 0.21 2.36 ± 1.53 0.067
Desoxycorticosterone 8.47 ± 3.50 12.69 ± 2.89 0.216 2.03 ± 0.64 11.60 ± 7.49 0.008
Corticosterone 405.55 ± 81.94 617.35 ± 137.48 0.128 254.47 ± 42.62 699.43 ± 313.30 0.002
Aldosterone 0.42 ± 0.13 0.57 ± 0.15 0.382 0.41 ± 0.12 1.01 ± 0.94 0.154
Testosterone 0.12 ± 0.05 0.10 ± 0.03 0.770 11.53 ± 6.22 0.04 ± 0.03 0.015
Estrone 0.11 ± 0.02 0.0 ± 0.0 0.001 — — —
Table 1. Hormonal measurement in WT and KO mice in plasma levels by LC-MS/MS.
XX mice
P-value
XY mice
P-value
Cyp17A 
(+/+) (n = 7) 
(mean ± SEM)
Cyp17A 
(d/d) (n = 6) 
(mean ± SEM)
Cyp17A 
(+/+) (n = 6) 
(mean ± SEM)
Cyp17A (d/d) 
(n = 12) 
(mean ± SEM)
Body weight (in g) 22.40 ± 0.75 26.20 ± 0.54 0.001 32.25 ± 0.43 34.15 ± 1.14 0.269
HDLC (mmol/l) 1.01 ± 0.09 1.06 ± 0.06 0.652 1.27 ± 0.13 1.32 ± 0.05 0.700
LDLC (mmol/l) 0.19 ± 0.01 0.15 ± 0.01 0.023 0.11 ± 0.02 0.19 ± 0.01 0.003
Total Cholesterol 
(mmol/l) 2.29 ± 0.20 2.31 ± 0.13 0.947 2.43 ± 0.29 3.17 ± 0.15 0.039
Triglycerides (mmol/l) 0.73 ± 0.04 0.75 ± 0.03 0.666 0.84 ± 0.09 0.80 ± 0.03 0.588
Table 2. Body weight and various lipid parameter levels measurement in WT and KO.
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(mean ± SD: 0.22 ± 0.12 vs. 1.47 ± 0.46 g) and WTD (0.31 ± 0.19 vs. 1.81 ± 0.66 g) (Fig. 2). In XY KO mice a sig-
nificant increase in visceral fat was only observed in mice feeding the chow diet.
We also determined the level of estrogen parameters including Estrone (E1), Estradiol (E2) and Estriol (E3) 
in XX mice in each group of Cyp17a1(d/d) x Apoe(d/d) and Cyp17a1(+/+) x Apoe(d/d)) under chow diet. Due to 
the low sensitivity of the assay, we were only able to detect measurable Estrone (E1). The Cyp17a1 KO mice lack 
Estrone compared to WT (Table 1).
Lipid parameters in CYP17A1-deficient mice on the Apoe(d/d) atherogenic background. As shown in Table 3, 
mice fed with a WTD for 8 weeks exhibited demonstrable increases in total cholesterol and LDLC, as expected; 
however, in contrast to mice on a non-atherogenic background, no significant differences were observed between 
the genotypes in total cholesterol or LDLC in animals of either chromosomal sex. Also, no differences in triglyc-
erides were detected between mice with different genotypes. Only a slight but significant difference in TC was 
observed in XX Cyp17a1 (d/d) x Apoe (d/d) compared to Cyp17a1 (+/+) x Apoe (d/d) at the age of 8 weeks 
before starting with WTD diet (Table 3).
CYP17A1-deficiency on an Apoe KO genetic background leads to increased atherosclerosis in XY but not in XX 
mice. First, we assessed atherosclerotic plaques in the aortic root. As expected, we detected an increase in ather-
osclerotic deposits after consumption of the WTD compared with standard chow in all groups (Fig. 3a). Analysis 
Figure 2. Body weight and visceral fat in Cyp17a1 KO and WT mice on an Apoe KO atherogenic background. 
Body weight and visceral fat were assessed in mice at 10 weeks old, before dietary differentiation, and after 8 
weeks consuming a WTD or a standard chow diet. ns, not significant.
Lipid 
parameter Status
XX mice
P-value
XY mice
P-value
Cyp17a1 (+/+) x 
Apoe (d/d) (n = 7) 
(mean ± SEM)
Cyp17a1 
(d/d) x Apoe 
(d/d) (n = 7) 
(mean ± SEM)
Cyp17a1 (d/d) x 
Apoe (d/d) (n = 7) 
(mean ± SEM)
Cyp17a1 
(+/+) x Apoe 
(d/d) (n = 6) 
(mean ± SEM)
TC
Pre-Diet 6.59 ± 0.30 7.56 ± 0.19 <0.001 7.68 ± 0.48 7.72 ± 0.51 0.961
Post-Chow 7.08 ± 0.76 7.02 ± 0.40 0.944 9.48 ± 1.24 8.84 ± 1.08 0.718
Post-WTD 20.83 ± 0.92 22.24 ± 1.27 0.433 22.14 ± 1.45 19.61 ± 2.40 0.372
LDLC
Pre-Diet 3.3 ± 0.28 4.03 ± 0.25 0.062 3.96 ± 0.38 3.78 ± 0.36 0.734
Post-Chow 3.7 ± 0.29 4.27 ± 0.29 0.202 4.64 ± 0.55 5.88 ± 0.18 0.063
Post-WTD 9.73 ± 0.83 10.41 ± 0.70 0.540 11.00 ± 0.55 10.77 ± 1.06 0.845
HDLC
Pre-Diet 0.69 ± 0.04 0.63 ± 0.04 0.225 0.68 ± 0.03 0.68 ± 0.04 0.963
Post-Chow 0.77 ± 0.44 0.44 ± 0.04 0.432 3.25 ± 1.23 0.55 ± 0.09 0.062
Post-WTD 0.28 ± 0.04 0.37 ± 0.05 0.149 0.47 ± 0.09 0.45 ± 0.06 0.867
TG
Pre-Diet 1.3 ± 0.24 1.43 ± 0.11 0.576 1.41 ± 0.12 1.38 ± 0.14 0.855
Post-Chow 1.46 ± 0.24 1.16 ± 0.05 0.222 2.77 ± 0.51 1.90 ± 0.18 0.143
Post-WTD 2.1 ± 0.16 2.11 ± 0.24 0.950 2.55 ± 0.89 2.18 ± 0.42 0.262
Table 3. Lipid parameter levels measurement in WT and KO on Apoe (d/d) genetic background after feeding a 
WTD.
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of the lesion area in aortic roots from XY mice lacking CYP17A1 revealed a large number of vascular lesions 
in those consuming both the WTD and chow diet, relative to controls (Fig. 3a). No difference in atheroscle-
rotic deposits was detected between XX mice of different genotypes consuming either chow or WTD. Similarly, 
remarkably significant differences in atherosclerotic deposits were also detected by en-face quantification of the 
whole aorta between XY mice in the Cyp17a1 KO and WT groups (Fig. 3b).
Lipid metabolic profiling. Atherosclerosis is believed to be caused by disorders of lipid metabolites. Therefore, 
we focused on XY mice and conducted mass spectrometry analysis to profile 234 lipid species in plasma sam-
ples. Twenty-eight lipid species showed distinct profiles between Cyp17a1(d/d) x Apoe(d/d) and Cyp17a1(+/+) 
x Apoe(d/d) mice. After using Bonferroni-corrected P-value threshold of 2.1 × 10−4 (0.05/234 all lipid species), 
only the ceramide species, Cer (d40:1) (d18:1/22:00), differed significantly between the two groups (Fig. 4).
Discussion
CYP enzymes have crucial roles in steroid hormone synthesis; hence any genetic variation affecting them influ-
ences the balance of hormone synthesis, leading to various DSDs. Such disorders are also associated with var-
ious cardiovascular risk factors, including hypertension32–37, diabetes, and aortic stiffness38. Here we focused 
on CYP17A1, a gene mapping to a locus associated with various cardiovascular disorders, including CAD, MI, 
diabetes, and arterial stiffness, according to GWAS3,33,34,38–40.
We knocked out the Cyp17a1 gene in mice and characterized various parameters in KO animals. In con-
trast to a previous publication reporting embryonic lethality in CYP17A1-deficient mice41, our mice survived 
to adulthood. This is corroborated by the fact that in humans, severe mutations of CYP17A1 cause complete 
17α-hydroxylase/17,20-lyase deficiency (17OHD), leading to disrupted steroidogenesis in adrenals and gonads 
and consequently to a rare form of DSD, but are compatible with life. We confirmed the expected steroid synthe-
sis imbalance in our mice and observed a sex development disorder, resembling the human phenotype. XY KO 
mice lacked testosterone and appeared phenotypically females. The 17,20 lyase activity of CYP17A1 as well as the 
availability of 17-hydroxysteroid substrates, which are exclusive products of CYP17A1 are essential for the pro-
duction of androgens and estrogens30. Like humans with severe 17OHD, mice deficient in CYP17A1 are infertile. 
Male Cyp17a1 KO mice have small testis and lacking Wolffian derivates and female Cyp17a1 KO mice display 
underdeveloped uteri (Supplemental Fig. 4). Spontaneous fertility in woman with CYP17A1 deficiency has not 
been reported42, but a successful live birth after in vitro fertilization, embryo transfer and adequate endometrial 
preparation had been achieved43. Therefore, this mouse model reflects in many aspects the DSD phenotype of 
human 17OHD.
Here, we were interested in the impact of lack of testosterone on atherosclerosis and related risk factors, 
such as lipid parameters. CAD is a complex disease involving numerous modifiable and un-modifiable risk fac-
tors1,44,45. Men are more susceptible to, and likely to die of CAD than women of a similar age. The male-to-female 
ratio of mortality from vascular disease is approximately 3:1 worldwide46. Previous studies indicate that low level 
or absent testosterone is associated with an increase in CAD events18–20,47,48, and testosterone declines with obesity 
and age47. An increase in atherosclerotic plaque deposition was detected in XY mice lacking CYP17A1, and con-
sequently lacking testosterone, suggesting a protective role for this hormone against atherosclerotic plaque for-
mation. This is consistent with the recent report from Steinfeld and co-workers49, who demonstrated low plasma 
Figure 3. Atherosclerosis analyses in mice fed chow or WTD. (a) Quantification of plaque deposits in aortic 
roots and representative images after Oil Red O staining (red). (b) Oil Red O quantification and staining of 
atherosclerotic lesions in the whole aorta of WTD fed mice. ns, not significant.
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levels of testosterone in the Apoe and Ldlr mouse KO models for atherosclerosis, compared with non-atherogenic 
wild-type C57BL/6 controls in age-matched groups, receiving a standard chow diet. Further, our data are in line 
with those from previous studies of the effects of reduced testosterone levels in males castrated due to prostate 
cancer and in experimental mice50,51; in both cases, low testosterone led to increased atherosclerosis. This sug-
gests that the effect of CYP17A1 deficiency on atherosclerosis in males seems to be acting via lack of testosterone 
because Cyp17a1 is not or low expressed in cells playing a critical role in atherosclerosis including monocytes/
macrophages, smooth muscle cells and endothelial cells, as well as the plaque itself. Thus physiological testoster-
one replacement could be an option to rescue the phenotype in mice50 without any need of genetic modification 
of Cyp17a1 expression. Further these data support the GWAS finding that the chromosomal region containing 
the CYP17A1 gene is associated with CAD and pinpoint CYP17A1 as the causal gene at this locus2,39,40.
We initially found that absence of CYP17A1 was associated with elevated progesterone in XX KO mice. In 
addition, XX Cyp17a1 KO mice displayed increased body weight and a massive accumulation of visceral fat 
deposits. Many studies have reported that women exhibit decreased progesterone, along with increases in cho-
lesterol and body weight, after menopause52–54, and these factors increase the risk for CAD55. Surprisingly, no 
changes in atherosclerosis development were detected in XX Cyp17a1 KO mice, although previous studies 
reported enhanced atherosclerosis in castrated females56–58. This may suggest that high level of progesterone in 
XX Cyp17a1 KO mice may play an atherprotective role.
LDLC was the only factor observed to be decreased in both chromosomal sexes as a result of knocking out 
Cyp17a1. Low testosterone and estrogen parameters (E1–3) levels are predictive for the development of the met-
abolic syndrome and its consequence on CVD in men and women, respectively. This study aimed to investigate 
the influence of testosterone deficiency on atherosclerosis in males. However and due to the interesting obesity 
phenotype in XX Cyp17a1 KO, we tried to determine the level of E1–3 in remaining plasma material in XX 
Cyp17a1 KO mice on an Apoe genetic background and under chow diet. The analysis revealed a complete absence 
of Estrone (E1) in XX Cyp17a1 KO mice as compared to the WT and are in line with previous work on ova-
riectomiszd females59. We were not able to detect E2–3 in our samples even in WT more likely due to the assay 
Figure 4. Heatmap representing lipid species showing differences in levels between XY mice with a Cyp17a1 
(d/d) x Apoe (d/d) (dbKO) and Cyp17a1 (+/+) x Apoe (d/d) (Apoe_KO) genotype. Lipids were extracted from 
plasma samples and evaluated by LC-MS. The levels of each lipid species were set from 0 to 1. The heatmap 
shows the difference in levels of lipid species between CYP17A1 deficient double KO mice (dbKO) and controls 
(Apoe_KO) mice. The asterisk (*) indicates lipid species with significantly different levels after correction for 
multiple testing (Bonferroni-corrected P-value threshold of 2.1 × 10−4 (0.05/234 all lipid species)).
9Scientific RepoRtS |         (2020) 10:8792  | https://doi.org/10.1038/s41598-020-65601-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
sensitivity limitation. The dysregulation of estrogen metabolism has also been associated with the susceptibility 
to obesity. Menopause associated reductions in estrogen are linked to a significant increase in the incidence of 
obesity53. Exogenous estrogen attenuates ovariectomy induced weight gain in mouse models60. Future studies are 
required to study the effect of Estradiol supplementation on obesity in our mouse model.
To understand the mechanisms underlying the association between low testosterone and atherosclerosis, we 
tested the effects of CYP17A1-deficiency on lipid metabolism, as a plausible contributor to atherosclerosis in our 
mouse model. We analyzed mice on both non-atherogenic and atherogenic Apoe backgrounds, fed with either 
standard chow or a WTD. We observed alterations of both total and LDLC levels after knocking out Cyp17a1, 
particularly in non-atherogenic males; however, no big differences were observed in mice on the atherogenic 
background. This may be due to the boost in cholesterol driven by consumption of the WTD; however, lipid-
omic profiling only demonstrated significant changes in one specific ceramide species Cer (d40:1) (d18:1/22:00), 
using Bonferroni-corrected P-value threshold of 2.1 × 10–4 (0.05/234 all lipid species) between Cyp17a1(d/d) 
x Apoe(d/d) XY mice and Apoe(d/d) littermate controls fed the WTD. The role of ceramides in atherosclerosis 
has been reported previously61. Together with fatty acids, ceramide forms the backbone of sphingolipids, which 
are key to the initiation and development of atherosclerosis61. Ichi et al. previously reported an association of 
ceramides in human plasma with risk factors for atherosclerosis62. The exact role of Cer (d40:1) (d18:1/22:00) 
remains to be determined in future studies.
In this study, we generated a Cyp17a1 KO mouse model of the rare form of the human DSD, caused by muta-
tions in CYP17A1. The KO mice were non-fertile, due to a defect in sex hormone biosynthesis, and exhibited 
higher corticosterone levels in XY mice. It is conceivable that corticosterone release was stimulated by inflamma-
tory cytokines and nutritional overflow which in turn accelerates the development of atherosclerotic changes in 
double Cyp17a1-ApoE double-knockout XY mice. Corticosterone accelerates atherosclerosis in the apolipopro-
tein E-deficient mouse63.
In addition our KO mice were not embryonic lethal. Here we investigated the effects of low testosterone in 
males on atherosclerosis and lipid metabolism in more details. Our data demonstrate that CYP17A1 influences 
lipid levels, likely contributing to the role of this factor in influencing CAD risk.
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